This milestone comes at a time when deaths resulting from synthetic opioid overdose are at record highs, and follows the US Food and Drug Administration 's recent Competitive Generic Therapy and Fast Track designations for Purdue's nalmefene HCl injection for the emergency treatment of known or suspected opioid overdose, which were announced earlier this year.
The NAL1002 study is part of Purdue's development program and plan to make nalmefene HCl injection available as quickly as possible to the patients who need it most.
As part of the programme, Purdue is developing nalmefene HCl injection as a generic product in vial and pre-filled syringe formats, and as an autoinjector through the 505(b) (2) pathway.
The first participant has now been enrolled and dosed in NAL1002, a Phase 1 study evaluating the pharmacokinetic and pharmacodynamic responses to various formulations of nalmefene HCl.
The first part of this study will compare pharmacokinetic profiles from healthy adult male and female subjects following administration of nalmefene HCl intramuscularly and intravenously at various doses. Initial results from the study are expected in Q3.
Nalmefene HCl has a longer duration of action than naloxone, another opioid antagonist currently approved for emergency treatment of known or suspected opioid overdose.
If approved, nalmefene HCl injection has the potential to serve as an important alternative for the treatment of opioid overdose.
Purdue established Imbrium Therapeutics L.P. to further advance its emerging portfolio and develop its pipeline in the areas of CNS, non-opioid pain medicines, and select oncology through internal research, strategic collaborations and partnerships.
Purdue's subsidiaries also include Adlon Therapeutics L.P., focused on treatment for Attention-Deficit/Hyperactivity Disorder and related disorders, and Greenfield Bioventures L.P., an investment vehicle focused on value-inflection in early stages of clinical development.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling